N'-[(E)-(3,4-dimethoxyphenyl)methylidene]-2-(naphthalen-1-yl)acetohydrazide

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N'-[(E)-(3,4-dimethoxyphenyl)methylidene]-2-(naphthalen-1-yl)acetohydrazide
• 英文别名: N-[(E)-(3,4-dimethoxyphenyl)methylideneamino]-2-naphthalen-1-ylacetamide
• 化学式: C₂₁H₂₀N₂O₃
• 分子量: 348.4
• InChiKey: MMJUJYOIYOJEPL-HYARGMPZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  59.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Hydrazone derivatives and uses thereof
  申请人：Bryant W. Robert

  公开号：US20070207093A1

  公开（公告）日：2007-09-06

  The present invention is directed to the use of a compound having the formula wherein R 1 , R 2 , R 3 , R 4 , L 1 , and L 2 are defined herein. The compounds of the present invention are useful as inhibitors of certain taste perceptions and functions. The invention is also directed to compositions comprising a compound according to the above formula.

  本发明涉及使用具有以下式子的化合物，其中R1，R2，R3，R4，L1和L2在此定义。本发明的化合物可用作某些味觉感知和功能的抑制剂。本发明还涉及包含上述式子的化合物的组合物。
• USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE
  申请人：Redpoint Bio Corporation

  公开号：EP2107908A2

  公开（公告）日：2009-10-14
• Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release
  申请人：Lee S. Paul

  公开号：US20080306030A1

  公开（公告）日：2008-12-11

  The present invention is directed to methods of enhancing insulin release, GLP-1 release, and insulin sensitivity, methods of increasing insulin gene expression, methods of decreasing gastric secretion and emptying and glucagons secretion, and methods of inhibiting food intake, and methods of treating diabetes mellitus, insulin resistance syndrome, hyperglycemia, and obesity comprising administering to a subject an effective amount of a TRPM5 inhibitor.
• US8193168B2
  申请人：——

  公开号：US8193168B2

  公开（公告）日：2012-06-05
• [EN] USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE<br/>[FR] UTILISATION D'UN INHIBITEUR DE TRPM5 POUR RÉGULER UNE SÉCRÉTION D'INSULINE ET DE GLP-1
  申请人：REDPOINT BIO CORP

  公开号：WO2008097504A2

  公开（公告）日：2008-08-14

  [EN] The present invention is directed to methods of enhancing insulin release, GLP-1 release, and insulin sensitivity, methods of increasing insulin gene expression, methods of decreasing gastric secretion and emptying and glucagons secretion, and methods of inhibiting food intake, and methods of treating diabetes mellitus, insulin resistance syndrome, hyperglycemia, and obesity comprising administering to a subject an effective amount of a TRPM5 inhibitor.
  [FR] L'invention concerne des procédés d'amélioration d'une sécrétion d'insuline, d'une sécrétion de GLP-1, et d'une sensibilité à l'insuline, des procédés d'augmentation de l'expression du gène d'insuline, des procédés de diminution de sécrétion et de vidange gastrique, et de diminution de sécrétion de glucagons, des procédés d'inhibition de prise alimentaire, et des procédés de traitement du diabète sucré, du syndrome d'insuline-résistance, de l'hyperglycémie et de l'obésité, comprenant l'administration à un sujet d'une quantité efficace d'un inhibiteur de TRPM5.